☆ 4.7 Review

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

EUROPEAN JOURNAL OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study

Jean marc Phelip et al.

Summary: This study compared triplet chemotherapy with doublet chemotherapy in advanced biliary tract cancer treatment, with the results showing triplet chemotherapy did not meet the primary study endpoint. Doublet chemotherapy remains the first-line standard in advanced BTC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation

Tanios S. Bekaii-Saab et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

Milind M. Javle et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

Laura Izquierdo-Sanchez et al.

Summary: This study investigates the clinical course of cholangiocarcinoma in a pan-European cohort and finds that the disease is frequently diagnosed at an advanced stage and a proportion of patients fail to receive cancer-specific therapies, resulting in a poor prognosis.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary

Alicia-Marie Conway et al.

Summary: A study conducted in a UK cancer center found that 34% of patients with liver-involved cancer of unknown primary (pCUP) met radiological criteria for an intrahepatic cholangiocarcinoma (iCCA) diagnosis. Patients were mostly female with an average age of 63, and both the iCCA group and the rest of the liver-involved CUP group had similar median overall survival.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

Funda Meric-Bernstam et al.

Summary: Futibatinib, a selective FGFR1-4 inhibitor, showed clinical activity in various solid tumors, particularly in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. It also demonstrated efficacy in patients who developed resistance to prior FGFR inhibitors. These findings provide a basis for further clinical trials and highlight the importance of genomic profiling in identifying patients who may benefit from targeted therapy.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.

Lipika Goyal et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).

Akihiro Ohba et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Current epidemiology of cholangiocarcinoma in Western countries

Mathew Vithayathil et al.

Summary: Cholangiocarcinomas are cancers that originate from the bile ducts and can occur within or outside the liver. In Western countries, the death rate due to intrahepatic cancers is rising at a higher rate than that of extrahepatic cancers, possibly due to an increase in cases of liver disease and misclassification of cancer types.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

Vivek Subbiah et al.

Summary: Pralsetinib is a potent and selective inhibitor of RET receptor tyrosine kinase, showing promising efficacy in patients with diverse RET fusion-positive solid tumors. It demonstrates rapid, robust, and durable anti-tumor activity, regardless of tumor type or RET fusion partner.

NATURE MEDICINE (2022)

添加到收藏夹

Meeting Abstract Oncology

Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC plus FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial

A. Lamarca et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Vivek Subbiah et al.

Summary: This study investigated the efficacy and safety of Selpercatinib in patients with RET fusion-positive non-lung or thyroid advanced solid tumors. The results showed that Selpercatinib demonstrated clinically meaningful activity in the RET fusion-positive tumor-agnostic population, with a safety profile consistent with other indications.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

Kyaw Z. Thein et al.

Summary: This study conducted a comprehensive analysis of KRAS(G12C) mutations in different types of cancer through liquid biopsy. The results showed that KRAS(G12C) mutations were detected in various cancers, with the highest detection rate in lung cancer.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Health Care Sciences & Services

Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis

Cindy Neuzillet et al.

Summary: This study analyzed a French nationwide prospective hospitalization database to investigate the epidemiology and patterns of care for intrahepatic cholangiocarcinoma (iCCA). The findings revealed a higher number of iCCA cases than previously reported, emphasizing the severity of this disease. The study also described the healthcare trajectories of patients, including surgery, chemotherapy, and best supportive care, in different healthcare settings.

LANCET REGIONAL HEALTH-EUROPE (2022)

添加到收藏夹

Article Oncology

Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors

Morten Lapin et al.

Summary: In patients with IDH-mutated advanced cholangiocarcinoma, detection of IDH mutations in ctDNA is feasible and dynamic changes in ctDNA may correspond with the clinical course and clonal evolution. High detection rates were observed using ddPCR and NGS for analyzing ctDNA samples.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.

Shubham Pant et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase III study of NUC-1031+cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Jennifer J. Knox et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)

Mairead G. McNamara et al.

Summary: The combination of NUC-1031 with cisplatin in the treatment of advanced biliary tract cancer (ABC) showed favorable safety profile in the initial study, with 725 mg/m(2) NUC-1031 recommended for phase III trial evaluation with cisplatin.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliarytract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study

Changhoon Yoo et al.

Summary: The addition of liposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival in advanced biliary tract cancer patients who had progressed on gemcitabine plus cisplatin. Liposomal irinotecan plus fluorouracil and leucovorin could be considered as a standard-of-care second-line therapy for advanced biliary tract cancer, with manageable safety profile.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Angela Lamarca et al.

Summary: This study found that second-line FOLFOX chemotherapy can significantly improve overall survival in patients with advanced biliary tract cancer after progression on cisplatin and gemcitabine, indicating it should be considered as standard-of-care chemotherapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)

Jean Frederic Blanc et al.

Summary: This document summarizes the French Intergroup guidelines on the management of hepatocellular carcinoma (HCC) published in March 2019. Recommendations are graded in 3 categories based on the level of evidence from literature. Diagnosis and staging of HCC rely on clinical, biological, and imaging features, with treatment options varying based on tumor stage and liver function.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)

添加到收藏夹

Review Oncology

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Gianluca Rompianesi et al.

Summary: Cholangiocarcinoma (CCA) is a heterogeneous group of tumors with complex diagnosis, management, and poor prognosis. Liquid biopsy (LB) offers a less invasive and serially repeatable way to detect tumor biomarkers from fluid samples, providing real-time monitoring of tumor genetic profile or therapy response.

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group

L. Perkhofer et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle et al.

Summary: The study evaluated the activity of pertuzumab plus trastuzumab in patients with HER2-positive metastatic biliary tract cancer. The results showed a promising response rate and good tolerability, suggesting the need for further randomized, controlled trials in this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Precision therapy for RET-altered cancers with RET inhibitors

Kyaw Z. Thein et al.

Summary: RET is involved in physiological development and its activated mutations are potent drivers of cancer. Traditional treatment with MKIs has modest efficacy but notable toxicities. Novel RET inhibitors like selpercatinib and pralsetinib have shown success in the clinic, providing a promising future outlook.

TRENDS IN CANCER (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Oliver Clements et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.

Jin Won Kim et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma

Robert Montal et al.

JOURNAL OF HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou-Alfa et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer

Cindy Neuzillet et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

Vivek Subbiah et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

L. J. Wirth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

Angela Lamarca et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Circulating tumor DNA and liquid biopsy in oncology

David W. Cescon et al.

NATURE CANCER (2020)

添加到收藏夹

Article Oncology

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Rachna T. Shroff et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

C. Marchio et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes

Maeve A. Lowery et al.

CANCER (2019)

添加到收藏夹

Review Oncology

TRK inhibitors in TRK fusion-positive cancers

A. Drilon

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review

Audra N. Boscoe et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

Yi Zheng et al.

BRITISH JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

Maeve A. Lowery et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma

Chirag Nepal et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

Milind Javle et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

Jason D. Merker et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

Shumei Kato et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Review Oncology

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Loic Verlingue et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

Loic Verlingue et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Exosomes: Therapy delivery tools and biomarkers of diseases

Lucio Barile et al.

PHARMACOLOGY & THERAPEUTICS (2017)

添加到收藏夹

Review Oncology

New Horizons for Precision Medicine in Biliary Tract Cancers

Juan W. Valle et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Christophe Massard et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise

Supriya K. Saha et al.

ONCOLOGIST (2016)

添加到收藏夹

Article Oncology

Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Enterologues Oncologues

Bertrand Brieau et al.

CANCER (2015)

添加到收藏夹

Article Oncology

HER2/neu-directed therapy for biliary tract cancer

Milind Javle et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

添加到收藏夹

Review Oncology

Second-line chemotherapy in advanced biliary cancer: a systematic review

A. Lamarca et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

John Bridgewater et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Article Oncology

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

Frederic Fiteni et al.

CANCER MEDICINE (2014)

添加到收藏夹

Article Pathology

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

Jesse S. Voss et al.

HUMAN PATHOLOGY (2013)

添加到收藏夹

Article Oncology

Clinical Implications of the Cancer Genome

Laura E. MacConaill et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Review Oncology

Cholangiocarcinoma

Stefania Mosconi et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)

添加到收藏夹

Article Oncology

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

J. Harder et al.

BRITISH JOURNAL OF CANCER (2006)

添加到收藏夹

Review Medicine, General & Internal

Cholangiocarcinoma

SA Khan et al.

LANCET (2005)

添加到收藏夹

Article Oncology

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study

T André et al.

ANNALS OF ONCOLOGY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.